Form 4: Evolent Health CAO Reports Share Transactions

Evolent Health's Chief Accounting Officer, Aammaad Shams, reported share acquisitions from performance-based units and tax-related dispositions.

Summary

• Aammaad Shams, Chief Accounting Officer of Evolent Health, Inc. (EVH), reported several transactions involving Class A Common Stock.
• On March 1, 2026, 2,577 shares of Class A Common Stock were disposed of at a price of $3.25 per share to satisfy tax withholding obligations upon the vesting of restricted stock units.
• On March 2, 2026, 1,686 shares of Class A Common Stock were acquired at a price of $0 upon the settlement of performance-based share units (PSUs) awarded on March 1, 2024, following the certification of performance metrics by the Compensation Committee.
• Also on March 2, 2026, 850 shares of Class A Common Stock were disposed of at a price of $3.58 per share to satisfy tax withholding obligations upon the settlement of performance-based share units.
• On March 3, 2026, 4,311 shares of Class A Common Stock were disposed of at a price of $3.51 per share to satisfy tax withholding obligations upon the vesting of restricted stock units.
• Following these transactions, Mr. Shams beneficially owns 71,158 shares of Class A Common Stock.
• Additionally, on March 2, 2026, Mr. Shams was granted 55,173 performance-based share units (PSUs) at a target level, which may be earned based on stock price performance conditions from March 1, 2027, to February 28, 2029, subject to service-based conditions. The actual amount earned can range from 0% to 250% of the target.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the successful achievement of past performance metrics leading to share settlement and the ongoing alignment of executive incentives with future company performance through new PSU grants. It indicates stability in executive compensation practices.

Positives

• The Chief Accounting Officer received 1,686 shares from the settlement of performance-based share units, indicating the achievement of specified performance metrics.
• A new grant of 55,173 performance-based share units aligns management incentives with future stock price performance and long-term shareholder value.

Negatives

• A total of 7,738 shares of Class A Common Stock were disposed of across three separate transactions to cover tax withholding obligations related to vested restricted stock units and settled performance-based share units. This is a standard practice and not inherently negative.

Risks

• The newly granted performance-based share units (PSUs) are subject to stock price performance conditions and service-based conditions, meaning the actual number of shares earned could range from 0% to 250% of the target level, introducing variability in future compensation.

Future Outlook

The newly granted performance-based share units (PSUs) for the Chief Accounting Officer are tied to the achievement of certain stock price performance conditions from March 1, 2027, to February 28, 2029, indicating a forward-looking incentive structure for management.

Industry Context

StockSavvy.ai notes that the reported transactions are typical for executive compensation in the healthcare technology sector, involving a mix of restricted stock units and performance-based share units. This structure aims to align executive incentives with long-term company performance and shareholder interests, a common practice among publicly traded companies to attract and retain key talent.

Comparison to Industry Standards

• The use of performance-based share units (PSUs) and restricted stock units (RSUs) for executive compensation is a standard practice across many industries, including healthcare technology, aligning with compensation strategies seen at companies like Teladoc Health (TDOC) or Veeva Systems (VEEV).
• The structure, where PSUs can vest between 0% and 250% of target based on performance, is a common mechanism to incentivize superior results, similar to plans observed at major tech and healthcare firms.
• Tax withholding upon vesting/settlement of equity awards is a universal practice for equity compensation, ensuring compliance with tax obligations.

Corporate Governance

Related Party Transactions

• The transactions involve equity compensation for a key executive (Chief Accounting Officer), which is a standard form of related party transaction between the company and its management.

Stakeholder Impact

• Shareholders: The grant of performance-based share units aligns the Chief Accounting Officer's incentives with the company's stock price performance, potentially benefiting shareholders if performance targets are met.
• Employees: The compensation structure for a senior executive can set a precedent or reflect the broader compensation philosophy within the company.

Next Steps

• The newly granted performance-based share units will be subject to stock price performance conditions from March 1, 2027, to February 28, 2029, and service-based conditions.
• The Compensation Committee will certify the achievement of specified performance metrics for the new PSUs at the conclusion of their performance period.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, including the settlement of performance-based awards and new grants, along with tax-related share dispositions. While it indicates management's continued alignment with company performance, it does not present new information that would fundamentally alter the investment thesis or warrant a change in a seasoned investor's current position. The transactions are expected and do not suggest significant operational or strategic shifts.

Keywords

Evolent Health, EVH, Form 4, Insider Transaction, Chief Accounting Officer, Aammaad Shams, Performance-Based Share Units, PSUs, Restricted Stock Units, RSUs, Stock Compensation, Tax Withholding